Ankündigung • May 01
MEDIROM Healthcare Technologies Inc. announced delayed 20-F filing On 04/30/2026, MEDIROM Healthcare Technologies Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Ankündigung • Apr 24
MEDIROM Healthcare Technologies Inc., Annual General Meeting, May 29, 2026 MEDIROM Healthcare Technologies Inc., Annual General Meeting, May 29, 2026, at 09:01 Tokyo Standard Time. Location: 16f, tradepia odaiba, 2-3-1 daiba, minato-ku, tokyo, japan, Japan New Risk • Mar 15
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.96m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (89% accrual ratio). Market cap is less than US$10m (US$9.96m market cap). Valuation Update With 7 Day Price Move • Oct 29
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$2.07, the stock trades at a trailing P/E ratio of 61.4x. Average trailing P/E is 19x in the Consumer Services industry in the US. Total loss to shareholders of 65% over the past three years. Ankündigung • Oct 29
Medirom Healthcare Technologies Inc. Plans to Expand the Installation of the Orb, an Advanced Camera That Verifies Humanness, to 200 Stores MEDIROM Healthcare Technologies Inc. announced that as of October 23, 2025, the Company surpassed 10,000 verifications of World ID at its Re.Ra.Ku and other wellness salons throughout Japan. The Company plans to further expand the installation of the Orb, an advanced camera that verifies humanness, to 200 stores. MEDIROM has joined the "World," a "proof of human" protocol co-founded by Sam Altman and Alex Blania. As the number of World ID verifications increases, more individuals across society will be able to prove their humanness, enhancing the convenience and reliability of this new digital social infrastructure. Furthermore, the increase in such authentication transactions is expected to contribute to revenue growth. Reported Earnings • Oct 24
First half 2025 earnings released: JP¥87.38 loss per share (vs JP¥119 loss in 1H 2024) First half 2025 results: JP¥87.38 loss per share. Revenue: JP¥3.24b (down 6.7% from 1H 2024). Net loss: JP¥690.5m (loss widened 19% from 1H 2024). Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to US$2.50, the stock trades at a trailing P/E ratio of 20x. Average trailing P/E is 18x in the Consumer Services industry in the US. Total loss to shareholders of 58% over the past three years. Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to US$1.56, the stock trades at a trailing P/E ratio of 12.3x. Average forward P/E is 17x in the Consumer Services industry in the US. Total loss to shareholders of 74% over the past three years. Valuation Update With 7 Day Price Move • Sep 03
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to US$1.56, the stock trades at a trailing P/E ratio of 12.3x. Average forward P/E is 17x in the Consumer Services industry in the US. Total loss to shareholders of 75% over the past three years. Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to US$2.12, the stock trades at a trailing P/E ratio of 16.6x. Average forward P/E is 16x in the Consumer Services industry in the US. Total loss to shareholders of 69% over the past three years. New Risk • Jul 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.60m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.1x net interest cover). Share price has been highly volatile over the past 3 months (25% average weekly change). High level of non-cash earnings (97% accrual ratio). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (US$9.60m market cap). Ankündigung • Jun 13
MEDIROM Healthcare Technologies Regains Compliance with Nasdaq Continued Listing Requirements MEDIROM Healthcare Technologies Inc. reported that on June 4, it received a written notification from The Nasdaq Stock Market LLC (Nasdaq) notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). According to a release, on February 27, the Company received notice from Nasdaq that it was not in compliance with the minimum bid price requirement, which requires listed securities to maintain a minimum closing bid price of $1.00 per share. To regain compliance, the Company's American Depositary Shares, representing common shares of the Company (ADSs), were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company was provided 180 calendar days through August 26, to regain compliance. On June 4, Nasdaq confirmed that for the last 10 consecutive business days, from May 20, to June 3, the closing bid price of the Company's ADSs had been $1.00 per share or greater. Accordingly, Nasdaq informed the Company that the Company has regained compliance with Nasdaq Listing rule 5550(a)(2) and that this matter is now closed. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to US$1.53, the stock trades at a trailing P/E ratio of 11.6x. Average forward P/E is 15x in the Consumer Services industry in the US. Total loss to shareholders of 76% over the past three years. Valuation Update With 7 Day Price Move • May 20
Investor sentiment improves as stock rises 36% After last week's 36% share price gain to US$1.30, the stock trades at a trailing P/E ratio of 10x. Average forward P/E is 17x in the Consumer Services industry in the US. Total loss to shareholders of 81% over the past three years. Ankündigung • May 19
MEDIROM Healthcare Technologies Inc. to Report Fiscal Year 2024 Results on May 20, 2025 MEDIROM Healthcare Technologies Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on May 20, 2025 Ankündigung • Apr 25
MEDIROM Healthcare Technologies Inc., Annual General Meeting, May 30, 2025 MEDIROM Healthcare Technologies Inc., Annual General Meeting, May 30, 2025, at 09:01 Tokyo Standard Time. Location: tokyo Japan Ankündigung • Feb 18
MEDIROM Healthcare Technologies Inc. Provides Preliminary Earnings Guidance for the Year Ended December 31, 2024 MEDIROM Healthcare Technologies Inc. provided preliminary earnings guidance for the year ended December 31, 2024. The unaudited, preliminary total revenue for the year ended December 31, 2024 is expected to be approximately JPY 8.2 billion ($52.6 million), representing a projected increase of approximately JPY 1.4 billion ($9.2 million) from the total revenue reported in accordance with u.s. gaap for the year ended December 31, 2023. Such increase was primarily due to increase in sales of salons to investors, increased store outsourcing revenue from such sold salons, and increased revenue from the rehabilitation business which the company acquired in October 2024. New Risk • Jan 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 62% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-JP¥364m). Shareholders have been substantially diluted in the past year (62% increase in shares outstanding). Market cap is less than US$10m (US$7.23m market cap). Minor Risk Share price has been volatile over the past 3 months (18% average weekly change). Ankündigung • Dec 11
MEDIROM Healthcare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $5.005 million. MEDIROM Healthcare Technologies Inc. has completed a Follow-on Equity Offering in the amount of $5.005 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 2,860,000
Price\Range: $1.75
Discount Per Security: $0.13125 New Risk • Dec 11
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$8.10m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Negative equity (-JP¥364m). Market cap is less than US$10m (US$8.10m market cap). New Risk • Nov 15
New major risk - Negative shareholders equity The company has negative equity. Total equity: -JP¥364m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (42% average weekly change). Negative equity (-JP¥364m). Minor Risk Market cap is less than US$100m (US$13.3m market cap). Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to US$3.59, the stock trades at a trailing P/E ratio of 22.7x. Average trailing P/E is 18x in the Consumer Services industry in the US. Total loss to shareholders of 53% over the past three years. Valuation Update With 7 Day Price Move • Sep 26
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to US$3.24, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 21x in the Consumer Services industry in the US. Total loss to shareholders of 62% over the past three years. Valuation Update With 7 Day Price Move • Sep 04
Investor sentiment deteriorates as stock falls 29% After last week's 29% share price decline to US$4.14, the stock trades at a trailing P/E ratio of 25.5x. Average trailing P/E is 21x in the Consumer Services industry in the US. Total loss to shareholders of 37% over the past three years. Ankündigung • Aug 25
MEDIROM Healthcare Technologies Inc. has filed a Follow-on Equity Offering in the amount of $5.75 million. MEDIROM Healthcare Technologies Inc. has filed a Follow-on Equity Offering in the amount of $5.75 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock) Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 34% After last week's 34% share price decline to US$2.60, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 20x in the Consumer Services industry in the US. Total loss to shareholders of 62% over the past three years. New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (149% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (US$15.7m market cap). Board Change • Jul 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 3 highly experienced directors. Corporate Auditor Toshiaki Komatsu was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Ankündigung • May 01
MEDIROM Healthcare Technologies Inc. announced delayed 20-F filing On 04/30/2024, MEDIROM Healthcare Technologies Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Ankündigung • Apr 03
MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM) entered into a memorandum of understanding to acquire Japan Gene Medicine Corporation for ¥2.4 billion. MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM) entered into a memorandum of understanding to acquire Japan Gene Medicine Corporation for ¥2.4 billion on March 29, 2024. The MOU was executed on April 2, 2024. The deal is subject to consummation of due diligence. Definitive agreement is expected to be signed on May 31, 2024 , and the deal is expected to be completed on June 30, 2024. Ankündigung • Mar 12
MEDIROM Healthcare Technologies Inc., Annual General Meeting, Mar 29, 2024 MEDIROM Healthcare Technologies Inc., Annual General Meeting, Mar 29, 2024. Agenda: To amend the Company's Articles of Incorporation; to re-elect four directors to serve for the ensuing year as members of the Board of Directors; to re-elect three corporate auditors to serve for the ensuing four years as members of the Board of Corporate Auditors; and to approve the Company's 2024 Equity Incentive Compensation Plan. New Risk • Feb 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Negative equity (-JP¥414m). Earnings have declined by 1.3% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (US$28.6m market cap). New Risk • Dec 31
New major risk - Revenue and earnings growth Earnings have declined by 1.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-JP¥1.2b free cash flow). Negative equity (-JP¥414m). Earnings have declined by 1.3% per year over the past 5 years. Minor Risk Market cap is less than US$100m (US$27.9m market cap). Valuation Update With 7 Day Price Move • Dec 26
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to US$4.33, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 22x in the Consumer Services industry in the US. Total loss to shareholders of 71% over the past three years. New Risk • Dec 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Negative equity (-JP¥59m). High level of non-cash earnings (221% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (US$19.0m market cap). Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to US$7.28, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Consumer Services industry in the US. Total returns to shareholders of 22% over the past year. Reported Earnings • Jun 01
Full year 2022 earnings released Full year 2022 results: Revenue: JP¥6.95b (up 28% from FY 2021). Net income: JP¥149.0m (up JP¥1.14b from FY 2021). Profit margin: 2.1% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Ankündigung • Jan 21
MEDIROM Healthcare Technologies Inc. Provides Earnings Guidance for the Year Ended December 31, 2022 MEDIROM Healthcare Technologies Inc. provided earnings guidance for the year ended December 31, 2022. For the year, preliminary total revenue for the year ended December 31, 2022 is expected to be approximately JPY 6.5 billion ($49.3 million), representing a projected increase of JPY 1.1 billion ($8.3 million) from the total revenue reported in accordance with U.S. GAAP for the year ended December 31, 2021. Such increase was primarily due to the full-year revenue contribution of two subsidiaries, SAWAN and ZACC, which were acquired by during 2021, an increase in the revenue from sales of directly-owned salons to investors, which sales were commenced in the fourth quarter of 2021, and an increase in sales at directly-operated salons as a result of the recovery from COVID-19 in 2022. The preliminary operating income is expected to be approximately JPY 240 million ($1.8 million) for the year ended December 31, 2022, representing a projected increase of JPY 711 million ($5.4 million) from the operating loss reported in accordance with U.S. GAAP for the year ended December 31, 2021. Such increase was primarily due to the increase in total revenue outpacing the increase in operating expenses in 2022. Reported Earnings • Dec 12
First half 2022 earnings released First half 2022 results: Revenue: JP¥3.15b (up 48% from 1H 2021). Net loss: JP¥190.0m (loss narrowed 64% from 1H 2021). Ankündigung • Jul 02
MEDIROM Healthcare Technologies Receives Nasdaq Notification Regarding Minimum Market Value Deficiency On July 1, 2022, MEDIROM Healthcare Technologies Inc. (the “Company”) announced that it has received a written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated June 29, 2022, notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Listing Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of USD 35 million and Nasdaq Listing Rule 5810(c)(3)(C) provides that a failure to meet the minimum market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company from May 9, 2022 to June 28, 2022, the Company no longer meets the minimum market value requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided 180 calendar days, or until December 27, 2022, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance, the Company’s market value must exceed USD 35 million for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by December 27, 2022, the Company may be eligible for additional time to regain compliance, or may face delisting. The Company intends to monitor its market value between now and December 27, 2022 and intends to cure the deficiency within the prescribed grace period. During this time, The company expects that American Depositary Shares representing common shares of the Company will continue to be listed and trade on The Nasdaq Capital Market. Ankündigung • May 20
MEDIROM Healthcare Technologies Receives Notification from Nasdaq Related to Delayed Filing of Annual Report MEDIROM Healthcare Technologies Inc. announced that on May 17, 2022, as a result of its failure to timely file with the U.S. Securities and Exchange Commission (the “SEC”) its Annual Report on Form 20-F for the year ended December 31, 2021 (the “Form 20-F”), it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1). Nasdaq listing rules provide the Company with 60 calendar days from the date of the notice to submit a plan to regain compliance. The Company intends to file the Form 20-F prior to the expiration of the 60-day period. The Nasdaq notice has no immediate effect on the listing or trading of the Company’s American Depositary Shares representing its common shares on Nasdaq. As previously disclosed by the Company in its Form 12b-25 filed with the SEC on April 28, 2022, the Company was unable to file its Form 20-F by its original deadline without unreasonable effort or expense. The Company is working diligently on its plan to regain compliance and file its Form 20-F as soon as practicable. Ankündigung • Apr 23
MEDIROM Healthcare Technologies Regains Compliance with Nasdaq Listing Standard MEDIROM Healthcare Technologies Inc. (the “Company”), announced that it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) on April 19, 2022 informing the Company that it has regained compliance with theminimum market value of listed securities standard under Nasdaq Listing Rule 5550(b)(2) for continued listing on The Nasdaq Capital Market. On January 18, 2022, Nasdaq notified the Company that it had failed to maintain a minimum market value of listed securities of $35 million over the previous 30 consecutive business days as required by The Nasdaq Capital Market set in Listing Rule 5550(b)(2) (the “Rule”). Following its notification in January 2022, Nasdaq has determined that for 10 consecutive business days, from April 10, 2022 to April 19, 2022, the Company’s market value of listed securities has been $35,000,000 or greater. Accordingly, the Company has regained compliance with the Rule and the matter is now closed. Ankündigung • Jan 22
MEDIROM Healthcare Technologies Receives Nasdaq Notification Regarding Minimum Market Value Deficiency MEDIROM Healthcare Technologies Inc. announced that it has received a written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated January 18, 2022, notifying the Company that it is not in compliance with the minimum market value requirement set forth in Nasdaq Listing Rules for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of $35 million and Nasdaq Listing Rule 5810(c)(3)(C) provides that a failure to meet the minimum market value requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the market value of the Company from November 23, 2021 to January 14, 2022, the Company no longer meets the minimum market value requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided 180 calendar days, or until July 18, 2022, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance, the Company’s market value must exceed US$35 million for a minimum of 10 consecutive business days. In the event the Company does not regain compliance by July 18, 2022, the Company may be eligible for additional time to regain compliance, or may face delisting. The Company intends to monitor its market value between now and July 18, 2022 and intends to cure the deficiency within the prescribed grace period. During this time, The Company expects that American Depositary Shares representing common shares of the Company will continue to be listed and trade on The Nasdaq Capital Market. Ankündigung • Sep 24
MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM) entered into a share transfer agreement to acquire ZACC Kabushiki-Kaisha from all of the existing shareholders of ZACC Kabushiki-Kaisha for ¥370 million. MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM) entered into a share transfer agreement to acquire ZACC Kabushiki-Kaisha from all of the existing shareholders of ZACC Kabushiki-Kaisha for ¥370 million on August 31, 2021. MEDIROM Healthcare Technologies will acquire 100% of the shares of ZACC through a two-stage acquisition for total consideration of ¥370 million. The purchase price will be paid by cash on hand, and an initial payment of ¥69,013,698 was made on August 31, 2021. Payments of ¥152,986,302 and ¥148,000,000 will be made on October 1, 2021 and January 1, 2022, respectively. In the first stage, the shareholders of ZACC will transfer 60% of the common shares of ZACC to MEDIROM. At the second stage, the remaining shares of ZACC will be transferred to MEDIROM. The first stage of the acquisition is scheduled to close on October 1, 2021. The second stage is scheduled to close on January 1, 2022. Board Change • Jul 30
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Akira Nojima was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Ankündigung • May 02
MEDIROM Healthcare Technologies Inc. announced delayed 20-F filing On 04/30/2021, MEDIROM Healthcare Technologies Inc. announced that they will be unable to file their next 20-F by the deadline required by the SEC. Ankündigung • Mar 06
MEDIROM Healthcare Technologies Inc., Annual General Meeting, Mar 29, 2021 MEDIROM Healthcare Technologies Inc., Annual General Meeting, Mar 29, 2021, at 09:00 Tokyo Standard Time. Location: 16F, Tradepia Odaiba, 2-3-1 Daiba Minato-ku Tokyo Japan Agenda: To amend the Articles of Incorporation (Addition of the Business Purpose); to amend the Articles of Incorporation (Changing the Authorized Capital); and to elect five (5) Directors. Ankündigung • Dec 30
MEDIROM Healthcare Technologies Inc. has completed an IPO in the amount of $12 million. MEDIROM Healthcare Technologies Inc. has completed an IPO in the amount of $12 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 800,000
Price\Range: $15
Transaction Features: Sponsor Backed Offering 
